SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 3,251.85 |
| Enterprise Value ($M) | 3,170.99 |
| Book Value ($M) | 416.91 |
| Book Value / Share | 7.57 |
| Price / Book | 7.80 |
| NCAV ($M) | 322.98 |
| NCAV / Share | 5.86 |
| Price / NCAV | 10.07 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.35 |
| Return on Assets (ROA) | -0.21 |
| Return on Equity (ROE) | -0.33 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.93 |
| Current Ratio | 4.93 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 554.15 |
| Assets | 648.08 |
| Liabilities | 231.18 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 107.94 |
| Operating Income | -137.57 |
| Net Income | -107.35 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -83.47 |
| Cash from Investing | -183.04 |
| Cash from Financing | -24.09 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | New Enterprise Associates 15, L.P. | 6.80 | 0.00 | |
| 13G/A | Fmr Llc | 11.50 | -20.77 | |
| 13G/A | Vanguard Group Inc | 7.25 | 19.67 | |
| 13G/A | BlackRock, Inc. | 6.40 | -16.94 | |
| 13D/A | Elghandour Rami | 6.90 | 40.22 | |
| 13G | Ra Capital Management, L.p. | 5.20 | ||
| 13G/A | Perceptive Advisors Llc | 7.20 | -14.44 | |
| 13G/A | Paradigm Biocapital Advisors LP | 8.90 | 31.20 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 697,737 | 1,625,746 | 42.92 | |
| 201,782 | 636,248 | 31.71 | |
| 139,100 | 534,965 | 26.00 | |
| 326,479 | 1,119,615 | 29.16 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABOS – Acumen Pharmaceuticals, Inc. | ABUS – Arbutus Biopharma Corporation |
| ACAD – ACADIA Pharmaceuticals Inc. | ACRS – Aclaris Therapeutics, Inc. |
| ACT – Enact Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io